Woodcliff Lake, NJ, United States of America

Corina Dutcus

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Corina Dutcus. Retrieved from https://idiyas.com/inventor/corina-dutcus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Corina Dutcus: Innovator in Tumor Therapeutics

Introduction

Corina Dutcus is a prominent inventor based in Woodcliff Lake, NJ (US). She has made significant contributions to the field of tumor therapeutics, showcasing her expertise and dedication to advancing medical science.

Latest Patents

Corina Dutcus holds a patent for a novel tumor therapeutic agent. This innovative agent is designed for a combination therapy that includes lenvatinib, ifosfamide, and etoposide. Her work in this area highlights her commitment to developing effective treatments for cancer.

Career Highlights

Corina is currently employed at Eisai R&D Management Co., Ltd., where she continues to push the boundaries of research and development in oncology. Her career is marked by a focus on creating impactful solutions for patients battling tumors.

Collaborations

Throughout her career, Corina has collaborated with esteemed colleagues such as Kiyoshi Okamoto and Junji Matsui. These partnerships have further enriched her research and contributed to her success in the field.

Conclusion

Corina Dutcus is a trailblazer in the realm of tumor therapeutics, with a patent that underscores her innovative spirit. Her work not only reflects her expertise but also her commitment to improving patient outcomes in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…